DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with ...

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features ...

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system ...

In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM ...

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.

announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0% ...